Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

TriSalus Life Sciences Expects Sales To Grow In Excess Of 50% In 2024; Says Currently In The Process Of Obtaining Additional Liquidity To Fund Operations Through 2024

Author: Benzinga Newsdesk | March 11, 2024 05:23pm

TriSalus also expects to report cash and cash equivalents balances of approximately $11.8 million as of December 31, 2023. It expects to have sufficient liquidity to fund operations into the second quarter of 2024.

Posted In: TLSI